Skip to main content

Table 1 LINE-1 methylation level in colorectal cancer.

From: Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors

Clinical, pathologic or molecular feature

Total N

Mean

Standard deviation

P value^

All cases

869

61.4

9.6

 

Sex

   

0.19

Men

394 (45%)

61.0

9.0

 

Women

475 (55%)

61.8

10.1

 

Age (years)

   

0.35

< 60

196 (23%)

60.5

10.5

 

60-69

363 (42%)

61.7

8.7

 

≥70

310 (36%)

61.5

9.9

 

Body mass index (BMI, kg/m2)

   

0.96

< 30

667 (83%)

61.3

9.5

 

≥30

141 (17%)

61.4

9.1

 

Family history of colorectal cancer

   

0.005

(-)

657 (76%)

61.9

9.6

 

(+)

212 (24%)

59.7

9.1

 

Smoking status

   

0.99

Never

350 (41%)

61.4

10.1

 

Past or current

508 (59%)

61.3

9.2

 

Tumor location

   

0.024

Proximal colon (cecum to transverse)

370 (44%)

61.9

9.2

 

Distal colon (splenic flexure to sigmoid)

274 (33%)

60.1

9.7

 

Rectum

192 (23%)

62.3

9.4

 

Disease stage

   

0.015

I

196 (25%)

61.5

9.2

 

II

253 (33%)

62.5

9.2

 

III

226 (29%)

60.1

9.5

 

IV

103 (13%)

60.0

11.0

 

Tumor grade

   

0.43

Low

777 (91%)

61.3

9.4

 

High

79 (9.2%)

62.3

11.2

 

Mucinous component

   

0.002

0%

554 (65%)

60.7

9.3

 

1-49%

188 (22%)

61.3

10.0

 

≥50%

115 (13%)

64.1

9.3

 

Signet ring cell component

   

0.009

0%

796 (93%)

61.0

9.4

 

1-49%

48 (5.6%)

63.5

10.8

 

≥50%

14 (1.6%)

67.6

8.5

 

Crohn's-like reaction

   

0.002

Absent/mild

684 (92%)

61.1

9.5

 

Moderate/severe

62 (8.3%)

65.2

9.6

 

Peritumoral lymphocytic reaction

   

0.018

Absent/mild

744 (89%)

60.9

9.4

 

Moderate/severe

93 (11%)

63.6

10.3

 

Tumor infiltrating lymphocytes (TIL)

   

0.043

Absent/mild

740 (89%)

60.9

9.5

 

Moderate/severe

96 (11%)

63.2

10.2

 

MSI status

   

< 0.0001

MSI-low/MSS

728 (85%)

60.7

9.5

 

MSI-high

124 (15%)

64.7

8.9

 

CIMP status

   

< 0.0001

CIMP-0

408 (47%)

60.2

9.8

 

CIMP-low

333 (38%)

61.3

9.3

 

CIMP-high

128 (15%)

65.1

8.3

 

CIN status (in MSI-low/MSS cases)

   

0.0002

(-)

142 (25%)

63.7

9.6

 

(+)

436 (75%)

60.3

9.0

 

KRAS mutation

   

0.90

(-)

538 (63%)

61.3

9.6

 

(+)

319 (37%)

61.2

9.4

 

BRAF mutation

   

0.001

(-)

728 (87%)

60.8

9.3

 

(+)

108 (13%)

64.2

10.2

 

PIK3CA mutation

   

0.24

(-)

646 (85%)

61.1

9.7

 

(+)

118 (15%)

62.2

9.3

 

TP53 expression

   

0.096

(-)

488 (57%)

61.8

9.8

 

(+)

371 (43%)

60.7

9.3

 

CDKN1A (p21)

   

0.0002

Lost

682 (81%)

60.6

9.6

 

Expressed

158 (19%)

63.7

9.0

 

CTNNB1 (β-catenin) score*

   

0.47

0-2 (inactive)

482 (64%)

61.4

9.8

 

3-5 (active)

273 (36%)

60.9

9.3

 

PTGS2 (COX-2) expression

   

0.98

(-)

142 (16%)

61.3

11.2

 

(+)

719 (84%)

61.3

9.2

 

FASN expression

   

0.16

(-)

742 (88%)

61.1

9.7

 

(+)

99 (12%)

62.4

8.7

 
  1. ^ P value was calculated by t-test assuming unequal variances (for binary variables) or ANOVA (analysis of variance; for 3-category variables). * CTNNB1 score was calculated as previously described [24].
  2. There were cases with missing information in covariates. A p value for significance is adjusted to p = 0.0021 by Bonferroni correction for multiple hypothesis testing.
  3. CIMP, CpG island methylator phenotype; MSI, microsatellite instability; MSS, microsatellite stable.
Back to article page

Molecular Cancer

ISSN: 1476-4598